Frontier Bio advances past the first stage of an NIH competition with its brain barrier model

Frontier Bio advances past the first stage of an NIH competition with its brain barrier model

On July 21, Frontier Bio announced that it had won the first stage of the NIH Complement-ARIE competition. The company presented NeuroTraX-AI, a blood-brain barrier model built from human cells whose condition is assessed by an algorithm using standard microscopy images. The win brought a cash prize and advanced the company to the next stages of the competition, which has a total prize pool of 7 million dollars.

Reaching the bloodstream is not enough for a drug intended to act on the brain. It must also cross the blood-brain barrier, a layer of cells in the walls of blood vessels in the brain. This barrier protects the brain by allowing some substances to pass while blocking others. Before testing a candidate in humans, developers therefore need to determine whether it can reach brain tissue and whether it could damage this vascular protection.

Frontier Bio grows a human cell model of the neurovascular unit, which reproduces part of the environment surrounding a blood vessel in the brain. A standard microscope images the cells without dyes, and NeuroTraX-AI uses those images to quantify the condition of the barrier. According to the company, the system shows whether the barrier retains its properties, whether an intervention disrupts them, and whether the agent under study crosses the barrier.

In this system, an image of a cell culture becomes a measurement of the barrier's condition. Instead of reviewing images manually, a developer receives a quantitative result for early testing of a candidate in a human cell system. This test addresses a practical question: how does the substance behave at the boundary between the blood and the brain?

The Complement-ARIE competition supports laboratory and computational methods that could replace some animal experiments. The first stage selected a combination of a human barrier model and automated analysis of its images. For developers of treatments for brain diseases, this provides a way to decide earlier which candidates should proceed to the next round of testing.